Zealand Pharma

ZEAL.COApproved

Copenhagen, DenmarkFounded 1998zealandpharma.com

Zealand Pharma leverages its proprietary peptide platform to design and develop novel therapeutics, with a core focus on metabolic and gastrointestinal disorders. The company has achieved significant milestones, including the commercialization of V-Go® for diabetes and the advancement of a high-potential pipeline led by survodutide, a GLP-1/glucagon dual agonist with blockbuster potential in obesity. Strategic partnerships with Boehringer Ingelheim and a strong financial position underpin its strategy to become a leader in peptide therapeutics.

Market Cap

$3.1B

Founded

1998

Employees

300-500

Focus

RNA & Gene Therapy

ZEAL.CO · Stock Price

USD 287.60+193.85 (+206.77%)

Historical price data

AI Company Overview

Technology Platform

Proprietary peptide technology platform for the discovery and optimization of novel peptide therapeutics, with expertise in GLP-1 receptor biology and multi-agonist design.

Pipeline Snapshot

44 drugs in pipeline, 16 in Phase 3

Drug	Indication	Stage
dasiglucagon + GlucaGen	Hypoglycemia	Phase 3
Dasiglucagon + Placebo	Hypoglycemia	Phase 3
Dasiglucagon	Congenital Hyperinsulinism	Phase 3
dasiglucagon	Congenital Hyperinsulinism	Phase 3
Glepaglutide	Short Bowel Syndrome	Phase 3

Funding History

IPOUndisclosedUndisclosedMay 28, 2010

FDA Approved Drugs

ZEGALOGUENDAMar 22, 2021

ZEGALOGUE (AUTOINJECTOR)NDAMar 22, 2021

Opportunities

The primary growth opportunity lies in the successful global launch of survodutide for obesity and MASH, potentially generating multi-billion dollar revenues.

Further opportunities include expanding the label for survodutide, advancing next-generation candidates like the tri-agonist ZP8396, and leveraging the peptide platform to discover new medicines in adjacent therapeutic areas.

Risk Factors

Key risks include clinical trial failures for lead candidate survodutide, intense competition from larger pharmaceutical companies in core markets, regulatory hurdles, and execution risk in commercializing a major product.

The company is also dependent on its partner, Boehringer Ingelheim, for the development and commercialization of its most valuable asset.

Competitive Landscape

Zealand faces intense competition, particularly in obesity from Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide). Its differentiation strategy is based on survodutide's unique GLP-1/glucagon dual agonist mechanism, which may offer distinct efficacy and metabolic benefits. In MASH, it competes with a range of biotechs and pharma companies developing diverse mechanisms.

Publications

Pipeline

FDA Approvals